Table 2.
Recent preclinical studies employing CAR-NK cells against various hematological cancers.
| Serial No. | Tumor Type | Specific Target | Source of NK-cells | CAR composition | Clinical Outcomes | References |
|---|---|---|---|---|---|---|
| 1. | T cell malignancies | CD5 | NK-92 | CD28+4-1BB+CD3ζ | Inhibition and control of disease progression | (123) |
| 2. | B-cell malignancies | CD19 | PB-NK | CD28+4-1BB+CD3ζ | Complete elimination of leukemia after 48 h | (124) |
| 3. | B-cell malignancies | CD19 | PB-NK | 4-1BB+CD3ζ | Augmented cytotoxicity of NK cells | (118) |
| 4. | B-ALL | CD19 | PB-NK | CD28+CD3ζ | Complete and durable molecular remissions of pre-B-ALL | (125) |
| 5. | B-cell malignancies | CD19 | NK-92 | CD3ζ | Successful inhibition of disease progression | (126) |
| 6. | B-cell malignancies | CD19 | NK-92 | CD3ζ | Overcame NK resistance and markedly enhanced NK-cell-mediated killing | (98) |
| 7. | B-cell malignancies | CD19 | PB-NK | CD28+CD3ζ+IL15 | Superior cytotoxicity with up to 90% specific killing activity | (127) |
| 8. | B-cell malignancies | CD19 | NK-92 | 41BB-CD3ζ, | Specific and efficient lysis of leukemia cell lines and lymphoblasts | (117) |
| 9. | B-ALL | FLT3 | NK-92 | CD28+CD3ζ+iCasp9 | Remarkable inhibition of disease progression and high antileukemic activity | (128) |
| 10. | B-cell malignancies | CD19 | UCB-NK | 4-1BB+CD3ζ+iCasp9+IL15 | Efficient killing of CD19-expressing cell lines and primary leukemia cells with marked prolongation of survival | (129) |
| 11. | B-cell malignancies | CD20 | PB-NK | 4-1BB+CD3ζ | Significantly enhanced cytotoxicity and IFNγ production, extended survival time and reduced tumor size | (130) |
| 12. | Burkitt lymphoma | CD20 | PB-NK | 4-1BB+CD3ζ+IL15 | Significant anti-tumor effects and enhanced in vitro cytotoxicity | (119) |
| 13. | MM | CD-38 | NK-92 | CD28-41BB-CD3ζ | Specific lysis of CD38-expressing tumor cell lines and effective depletion of MM | (131) |
| 14. | MM | CD138 | NK-92MI | CD3ζ | Remarkable cytotoxicity against human MM cell lines and elevated secretion of granzyme B, interferon-γ and CD107a proportion | (120) |
| 15. | MM | CS-1 | NK-92 | CD28+CD3ζ | Enhanced MM cytolysis and IFN-γ production, efficient suppression of human IM9 MM cells and significant survival of mice | (132) |
| 16. | Peripheral T cell lymphoma | CD-4 | NK-92 | CD28-41BBCD3ζ | Specific elimination of T-cell leukemia, lymphoma cell lines, and patient samples ex vivo | (133) |
| 17. | T cell malignancies | CD-5 | NK-92 | 2B4-CD3ζ | Specific cytotoxicity against CD5+ malignant cells and prolonged survival of T-ALL xenograft mice | (134) |
| 18. | T-ALL | CD-7 | NK-92 | CD28-41BBCD3ζ | Potent anti-tumor activity, elevated Granzyme B and IFNγ secretion, and significant inhibition of disease progression | (135) |
| 19. | EBV+ T cell | EBNA3C | NK-92 | 4-1BB+CD3ζ | Exquisite specificity, potent cytotoxicity, and induction of ADCC toward the targeted T-cell epitope (TCE) | (121) |
| 20. | Non-Hodgkin’s lymphoma or chronic lymphocytic leukemia | CD-19 | UCB-NK | CD28+CD3ζ+ IL15+iCasp9 | complete remission in 7/11 (4 with lymphoma and 3 with CLL) | (122) |